What question did this study set out to answer?

This review aims to evaluate the efficacy of arterial spin-labeling MRI as a biomarker in neurodegenerative diseases.

June 13, 2026

Arterial Spin-labeling MRI as an Accessible Biomarker for Monitoring Neurodegenerative Disease Progression and Treatment Response (P1-13.005)

Key Points

This review aims to evaluate the efficacy of arterial spin-labeling MRI as a biomarker in neurodegenerative diseases.
Reviewed current studies supporting the use of ASL-MRI as a biomarker.
Compared ASL-MRI to other imaging modalities like FDG-PET and amyloid imaging.
ASL-MRI is shown to be a cost-effective and noninvasive alternative to FDG-PET.
Evidence supports ASL-MRI's effectiveness in monitoring disease progression and treatment response.

Abstract

To review the current evidence supporting arterial spin-labeling MRI (ASL-MRI) as a cost-effective, noninvasive biomarker for monitoring neurodegenerative disease progression and treatment response, emphasizing its role as an alternative to FDG-PET and amyloid imaging.

Arterial Spin-labeling MRI as an Accessible Biomarker for Monitoring Neurodegenerative Disease Progression and Treatment Response (P1-13.005)

Key Points

Abstract

Cite This Study

Also Consider

Also Consider